ANDA Amendments Cannot Get Mid-Review Communications Like Full Applications - FDA

 
• By Derrick Gingery
  
Sand running through the bulbs of an hourglass measuring the passing time in a countdown to a deadline, on a dark background with copy space.
Industry worries that lack of mid-review communication about minor deficiencies in ANDA amendments could lengthen approval times.
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA

More from Agency Leadership